Drugs / Nifuroxazide
Nifuroxazide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT05754996 | Mar 2023 → Jul 2025 | hepatic encephalopathy | Cairo University | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT05988528 Comparator | Aug 2023 → Feb 2025 | inflammatory bowel disease | Mostafa Bahaa | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nifuroxazide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05988528 ↗ |
| Known as | Ercefuryl 200 | ChEMBL registry synonym — accepted as the source's own label CHEMBL244888 ↗ |
| Known as | Nifuroxazida | ChEMBL registry synonym — accepted as the source's own label CHEMBL244888 ↗ |
| Known as | NSC-759261 | ChEMBL registry synonym — accepted as the source's own label CHEMBL244888 ↗ |
| Known as | RC-27109 | ChEMBL registry synonym — accepted as the source's own label CHEMBL244888 ↗ |
| Known as | SJ000287313 | ChEMBL registry synonym — accepted as the source's own label CHEMBL244888 ↗ |
| Modality | Small molecule | — CHEMBL244888 ↗ |
| Route | Oral | “Nifuroxazide is an oral broad-spectrum nitrofuran antibiotic” NCT05754996 ↗ |